Brooklyn ImmunoTherapeutics Inc
BTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.07B
Close$
$0.45
95.2% downside
Current Fair Value
95.2% downsideOvervalued by 95.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.07 Billion |
|---|---|
| Enterprise Value | $1.07 Billion |
| Dividend Yield | $0.63 (8.04%) |
| Earnings per Share | $0.17 |
| Beta | 1.34 |
| Outstanding Shares | - |
Return
| Return on Equity | -4.91% |
|---|---|
| Return on Assets | -4.79% |
| Return on Invested Capital | -2.02% |
Valuation & Multiples
| P/E Ratio | 55.51 |
|---|---|
| PEG | 14.77 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1790.89 |
| Enterprise Value to EBIT | -57.14 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Brooklyn ImmunoTherapeutics Inc
2,018 employeesBrooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to a...